title: Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
abstract: Hepatocellular carcinoma is the most common, malignant tumor of liver. Most cases of hepatocellular carcinoma are associated with either viral hepatitis or cirrhosis. But major risk factor for hepatocellular carcinoma in developing countries is mainly chronic hepatitis B. Sorafenib is one of the first-line drug which has been extensively used in metastatic and inoperable hepatocellular carcinoma. We report a rare case of spontaneous deep venous thrombosis of bilateral lower limbs as an important unrecognized side effect of sorafenib.
authors.affiliation: Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India.
authors.forename: Irappa
authors.initials: I
authors.lastname: Madabhavi
authors.forename: Apurva
authors.initials: A
authors.lastname: Patel
authors.forename: Asha
authors.initials: A
authors.lastname: Anand
authors.forename: Mukesh
authors.initials: M
authors.lastname: Choudhary
authors.forename: Swaroop
authors.initials: S
authors.lastname: Revannasiddaiah
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D011379:Prognosis; D000077157:Sorafenib; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib